PledPharma’s Nomination Committee wants board changes

PledPharma’s Nomination Committee has submitted a proposal for a new composition of the Board of Directors for consideration at an extraordinary shareholders meeting held on February 10, 2017

The Nomination Committee considers need for strengthened competence of the Board in the areas of Phase III clinical development and registration procedures, as the company decided to develop PledOx, its lead-candidate drug, through the final registration studies. Meanwhile, the company also has started a clinical study with Aladote – a candidate drug to reduce liver damage from paracetamol poisoning is being planned.

The Nomination Committee has proposed changes to the Board by new election of Gunilla Osswald, current CEO at BioArctic and Elisabeth Svanberg, general surgeon and associate professor of surgery and Chief Development Officer at Ixaltis SA.

Board members Håkan Åström (chairman) and Sten Nilsson will remain on the board.

The Nomination Committee consists of Staffan Persson (Chairman), Peter Lindell, Astrid Samuelsson and Håkan Åström (Adjunct).